Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

5.48
-0.0900-1.62%
Post-market: 5.26-0.2225-4.06%19:49 EDT
Volume:846.51K
Turnover:4.69M
Market Cap:123.54M
PE:-0.31
High:5.77
Open:5.51
Low:5.40
Close:5.57
52wk High:10.99
52wk Low:3.51
Shares:22.54M
Float Shares:21.40M
Volume Ratio:0.16
T/O Rate:3.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9300
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-41.56%
PB:-0.42
PE(LYR):-0.31

Loading ...

Karyopharm Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Mar 10

Karyopharm initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Mar 10

Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Mar 08

Karyopharm Therapeutics: Amendment to Eliminate Requirement That 50% of Financing Proceeds Be Applied Toward Increasing Minimum Liquidity Covenant

THOMSON REUTERS
·
Mar 03

Karyopharm Therapeutics Inc - Amendment Allows Co Deferral of Payments Until September 2026 - SEC Filing

THOMSON REUTERS
·
Mar 03

Karyopharm Therapeutics amends credit agreement with lenders and Wilmington Savings Fund Society

Reuters
·
Mar 03

Karyopharm Grants 1,450 RSUs to Newly Hired Employees Under Inducement Plan

Reuters
·
Mar 03

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 03

Piper Sandler Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Feb 19

Karyopharm Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 18

Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority

TIPRANKS
·
Feb 14

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Feb 14

UPDATE: Karyopharm Therapeutics Q4 Adj. EPS $(2.23) Misses $(1.99) Estimate

Benzinga
·
Feb 12

Karyopharm Therapeutics Showcases Pipeline Advances and Upcoming Phase 3 Data in Cancer Therapies

Reuters
·
Feb 12

BRIEF-Karyopharm Reports Fourth Quarter And Full Year 2025 Financial Results And Highlights Recent Company Progress

Reuters
·
Feb 12

Karyopharm Q4 revenue rises on XPOVIO demand

Reuters
·
Feb 12

Karyopharm Therapeutics Q4 EPS $(5.71) Misses $(1.99) Estimate, Sales $34.079M Miss $35.112M Estimate

Benzinga
·
Feb 12

Karyopharm reports FY 2025 total revenue of USD 146.07 million

Reuters
·
Feb 12

BRIEF-Karyopharm Therapeutics Q4 Net Income USD -102.198 Million

Reuters
·
Feb 12

Karyopharm Therapeutics Q4 Operating Expenses USD 51.923 Million

THOMSON REUTERS
·
Feb 12